Leiden, the Netherlands, April 25, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces the following presentations by the Company or its collaborators at the 2025 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 1-4, 2025 in Philadelphia, PA. These presentations include Phase III clinical data for leniolisib for pediatric patients aged 4-11 years with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) and insights into APDS and additional p ...

Welcome everyone to today's LinkedIn live. I'm Joti Swarup, chief marketing officer at DDN and I'm thrilled to have you here on what is my first LinkedIn live ever. So this is exciting for me personally. But what's more exciting and apt is that I have a special guest with me uh Moith Kohari who is the VP of AI and financial services at DDN and he spent years helping firms navigate the chaos of markets regulations and now uh transformative technology and AI. So Moyes I'll I'll let you uh introduce yourself t ...

终于，上海3月"小阳春"的楼市数据出炉了。 不过各位知道吗，真正的"隐忧"其实是在一年后，也就是2026年的4月。 据官方统计，上海 二手房累计成交29369套，略低于2024年最高的12月份，也是自2021年以来的又一小高峰，也让大家对接下来4月的成交，多了几份信 心。 01 都是哪些地方、哪些楼盘要"解禁" 2021年3月3日，上海新房正式实行限售政策，对认购比例超过130%的新盘，按照网签时间开始计算为期5年的限售期，让大家安安心心买了后，等上5年 再看要不要卖。 随后在4月20日开盘的闵行新城千禧公园，迅速成为了"限售"新政后的首个楼盘，单价4.04万/平，房源数一共328套，最终认购率高达348%，入围积分超 过66分。 因此，它也将成为2026年全上海首个"解禁"的新房，轰轰烈烈地揭开"解禁潮"的序幕。 数据整理自网络，仅供参考 当年各个新盘一共开盘了255次，光触发限售的就有119次，占比接近一半，总数加起来更是超过3.3万套，而且不乏多个热门红盘，包括吸引了 1300多人 摇号的 蟠龙天地二期，以及积分高达102分的翠湖天地五期。 往前数5年，2021年首批触发积分的上海新盘将正式进入二手市场 ...

TMC the metals company (TMC) Q4 2024 Earnings Call March 27, 2025 04:30 PM ET Company Participants Craig Shesky - CFOGerard Barron - Chairman and Chief Executive OfficerJake Sekelsky - MD & Head of Metals & Mining Research Conference Call Participants Matthew O'Keefe - AnalystDmitry Silversteyn - Senior Research Analyst Operator Good day, and thank you for standing by. Welcome to The Metals Company Fourth Quarter twenty twenty four Corporate Update Conference Call. At this time, all participants are in a li ...

Urban One (UONE) Q4 2024 Earnings Call March 27, 2025 10:00 AM ET Company Participants Alfred Liggins III - CEOPeter Thompson - Executive VP & CFOBen Briggs - DirectorMarlane Pereiro - High Yield Credit ResearchMatthew Swope - Managing DirectorKen Silver - Managing Director Conference Call Participants Aaron Watts - Managing Director, Media, Entertainment, Cable, & Satellite Credit AnalystHal Steiner - VP & Trading Desk Analyst Operator Ladies and gentlemen, thank you for standing by, and welcome to the Urb ...

Culp, Inc (NYSE:CULP) Q3 2025 Results Conference Call March 6, 2025 9:00 AM ET Company Participants Dru Anderson - Head of Investor Relations Robert Culp - President and Chief Executive Officer Kenneth Bowling - Chief Financial Officer Tommy Bruno - EVP of Culp Home Fashions Mary Beth Hunsberger - President, Culp Upholstery Fabric Division Conference Call Participants Brian Gordon - Water Tower Research Operator Good day, and welcome to the Culp, Inc. Third Quarter Fiscal 2025 Earnings Conference Call. [Ope ...

Core Insights - Editas Medicine is on track to declare two in vivo editing development candidates by mid-2025, one targeting hematopoietic stem cells (HSCs) and the other targeting liver cells [1][2] - The company has demonstrated preclinical proof of concept in non-human primates and humanized mice, showcasing the potential of its gene upregulation strategy across multiple tissues [3][6] - Editas maintains a strong cash position, with cash, cash equivalents, and marketable securities amounting to $269.9 million as of December 31, 2024, which is expected to fund operations into the second quarter of 2027 [4][17] Business Updates - The company achieved in vivo preclinical proof of concept ahead of schedule, indicating significant progress in its gene editing platform [2] - Editas plans to present further preclinical data for HSCs and liver indications by year-end 2025 [1][6] - The company is also on track to establish an additional target cell type or tissue by the end of 2025 [1][6] Financial Performance - For Q4 2024, Editas reported a net loss of $45.4 million, or $0.55 per share, compared to a net loss of $18.9 million, or $0.23 per share, in Q4 2023 [6][14] - Collaboration and other research and development revenues decreased to $30.6 million in Q4 2024 from $60.0 million in Q4 2023, primarily due to revenue recognized from a license agreement with Vertex Pharmaceuticals [6][14] - For the full year 2024, the net loss attributable to common stockholders was $237.1 million, or $2.88 per share, compared to a net loss of $153.2 million, or $2.02 per share, in 2023 [14][15] Restructuring and Cost Management - The company ended the development of its reni-cel program, leading to a workforce reduction of approximately 65% and restructuring charges of $12.2 million in Q4 2024 [6][7] - Research and development expenses decreased to $48.6 million in Q4 2024 from $69.6 million in Q4 2023, primarily due to reduced costs associated with the reni-cel program [6][14] Upcoming Events - Editas Medicine plans to participate in investor events, including the Leerink Partners Global Biopharma Conference and the Barclays 27th Annual Global Healthcare Conference in March 2024 [9]

Fuel Tech, Inc. (NASDAQ:FTEK) Q4 2024 Earnings Conference Call March 5, 2025 10:00 AM ET Company Participants Devin Sullivan - Managing Director, The Equity Group Vince Arnone - Chairman, President & Chief Executive Officer Ellen Albrecht - Chief Financial Officer Conference Call Participants Sameer Joshi - H.C. Wainwright Marc Silk - Silk Investment William Bremer - Vanquish Capital Markets Operator Greetings, and welcome to the Fuel Tech 2024 Fourth Quarter Financial Results Conference Call and Webcast. A ...

TEGNA Inc (NYSE:TGNA) Q4 2024 Results Conference Call February 27, 2025 9:00 AM ET Company Participants Kirk von Seelen - Investor Relations Mike Steib - Chief Executive Officer Julie Heskett - Chief Financial Officer Conference Call Participants Stephen Cahall - Wells Fargo Craig Huber - Huber Research Patrick Sholl - Barrington Research Marlane Pereiro - Bank of America Dan Kurnos - The Benchmark Company Operator Good day, and thank you for standing by. Welcome to the Q4 2024 TEGNA Inc. Earnings Conferenc ...

Tegna (TGNA) Q4 2024 Earnings Call February 27, 2025 09:00 AM ET Company Participants Kirk von Seelen - VP & TreasurerMike Steib - President & CEOJulie Heskett - Senior VP & CFOPatrick Sholl - Vice PresidentMarlane Pereiro - High Yield Credit Research Conference Call Participants Steven Cahall - Managing Director, Senior Analyst - Media, Advertising & CableCraig Huber - Equity Research AnalystDaniel Kurnos - Equity Research Analyst Operator Good day, and thank you for standing by. Welcome to the Q4 twenty t ...